| LTT BIO PHARMA CO., LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120034202 | AMELIORATING AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - An ameliorating agent for chronic obstructive pulmonary disease (COPD) containing as an active ingredient a lecithinized superoxide dismutase represented by the following general formula (I): | 02-09-2012 |
| 20120016158 | LOXOPROFEN DERIVATIVE AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME - There is provided a novel loxoprofen derivative that has no side effect such as a gastrointestinal disorder and also has excellent anti-inflammatory and analgesic effects and is represented by the following formula (I) or (II): | 01-19-2012 |
| 20110262548 | NOVEL PROSTAGLANDIN E1 DERIVATIVE AND NANOPARTICLE HAVING THE SAME ENCAPSULATED THEREIN - A PGE1 derivative is provided which has an excellent sustained, slow-release PGE1 action. In addition, a PGE1-derivative-containing nanoparticle produced using this PGE1 derivative is provided, which effectively targets an affected site, has excellent drug slow-release properties, and has reduced side effects. This PGE1-derivative-containing nanoparticle is a nanoparticle containing a prostaglandin E1 derivative represented by the following formula (1) | 10-27-2011 |
| 20110262420 | INHALANT COMPRISING MODIFIED SUPEROXIDE DISMUTASE - An inhalant containing a lecithinized superoxide dismutase (hereinafter referred to as PC-SOD) which effectively exerts the effect of superoxide dismutase (SOD) as an active ingredient, particularly for treatment of idiopathic (acute) or chronic interstitial pneumonia, is provided. The inhalant includes a PC-SOD represented by the following general formula (I): | 10-27-2011 |
| 20100143321 | THERAPEUTIC COMPOSITION FOR INTERSTITUAL PNEUMONIA - A therapeutic agent for interstitial pneumonia is provided which effectively exploits the effect of superoxide dismutase (SOD). The therapeutic composition for interstitial pneumonia contains 10 to 100 mg of lecithinized superoxide dismutase represented by the following general formula (I): | 06-10-2010 |
| 20100129456 | SUSTAINED-RELEASE NANOPARTICLE CONTAINING LOW-MOLECULAR-WEIGHT DRUG WITH NEGATIVELY CHARGED GROUP - A nanoparticle containing a low-molecular-weight drug having a negatively charged group is provided that is effectively targeted to an affected site, is capable of sufficiently sustained release of the drug, and has a reduced tendency to accumulate in the liver to cause reduced side effects. The nanoparticle containing a low-molecular-weight drug having a negatively charged group is obtained by hydrophobicizing the low-molecular-weight drug having a negatively charged group with a metal ion, and reacting the hydrophobicized drug with poly L-lactic acid or poly(L-lactic acid/glycolic acid) copolymer and poly DL- or L-lactic acid-polyethylene glycol block copolymer or poly(DL- or L-lactic acid/glycolic acid)-polyethylene glycol block copolymer. | 05-27-2010 |
